Kinase Expression One year post treatment [clinicaltrials_resource:c46f69db012ee0138a9e55eb07c5d8ac]
The primary outcome of this study is to identify kinases that are differentially expressed pre- and post-treatment with BRAF (dabrafenib) and MEK (trametinib) inhibitors. The kinases will be profiled using Multiplexed Inhibitor Beads (MIBs) coupled with mass spectrometry.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Kinase Expression One year post treatment [clinicaltrials_resource:c46f69db012ee0138a9e55eb07c5d8ac]
The primary outcome of this study is to identify kinases that are differentially expressed pre- and post-treatment with BRAF (dabrafenib) and MEK (trametinib) inhibitors. The kinases will be profiled using Multiplexed Inhibitor Beads (MIBs) coupled with mass spectrometry.
Bio2RDF identifier
c46f69db012ee0138a9e55eb07c5d8ac
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:c46f69db012ee0138a9e55eb07c5d8ac
measure [clinicaltrials_vocabulary:measure]
Kinase Expression
time frame [clinicaltrials_vocabulary:time-frame]
One year post treatment
description
The primary outcome of this st ...... oupled with mass spectrometry.
identifier
clinicaltrials_resource:c46f69db012ee0138a9e55eb07c5d8ac
title
Kinase Expression One year post treatment
@en
type
label
Kinase Expression One year pos ...... f69db012ee0138a9e55eb07c5d8ac]
@en